Myocardial Ischemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Myocardial Ischemia Pipeline Drugs Market Overview

Myocardial ischemia pipeline market research report provides comprehensive information on the therapeutics under development for Myocardial Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects.

Key Targets in the Myocardial Ischemia Pipeline Market

The key targets in the myocardial ischemia pipeline market are Adenylate Cyclase Type 5, Fibroblast Growth Factor 4, Gap Junction Alpha 1 Protein, N-Formyl Peptide Receptor 2, N-Formyl Peptide Receptor 3, Nitric Oxide Synthase Inducible, Protein Phosphatase 2A, Receptor Type Tyrosine Protein Phosphatase S, Transient Receptor Potential Cation Channel Subfamily M Member 7, and Vascular Endothelial Growth Factor A.

Key MoA in the Myocardial Ischemia Pipeline Market

The key MoA in the myocardial ischemia pipeline market are Adenylate Cyclase Type 5 Inhibitor, Fibroblast Growth Factor 4 Activator, Gap Junction Alpha 1 Protein Inhibitor, N-Formyl Peptide Receptor 2 Agonist, N-Formyl Peptide Receptor 3 Agonist, Nitric Oxide Synthase Inducible Inhibitor, Protein Phosphatase 2A Inhibitor, Receptor Type Tyrosine Protein Phosphatase S Inhibitor, Transient Receptor Potential Cation Channel Subfamily M Member 7 Blocker, and Vascular Endothelial Growth Factor A Activator.

Key RoA in the Myocardial Ischemia Pipeline Market

The key RoA in the myocardial ischemia pipeline market are  oral, intracardiac, intracoronary, intradermal, intravenous, parenteral, and topical. Oral has the highest number of pipeline products.

Myocardial Ischemia Pipeline Market, by RoA

Myocardial Ischemia Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the Myocardial Ischemia Pipeline Market

The key molecule types in the myocardial ischemia pipeline market are small molecule, recombinant protein, gene therapy, peptide, synthetic peptide, cell therapy, and oligonucleotide. Small molecule has the highest number of pipeline products.

Myocardial Ischemia Pipeline Market, by Molecule Types

Myocardial Ischemia Pipeline Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the Myocardial Ischemia Pipeline Market

The key companies in the myocardial ischemia pipeline market are Anagenics Ltd, Angionetics Inc, AstraZeneca Plc, BioCardia Inc, Chrysalis BioTherapeutics Inc, CohBar Inc, Eight Plus One Pharmaceutical Co Ltd.

Market report overview

Key targets Adenylate Cyclase Type 5, Fibroblast Growth Factor 4, Gap Junction Alpha 1 Protein, N-Formyl Peptide Receptor 2, N-Formyl Peptide Receptor 3, Nitric Oxide Synthase Inducible, Protein Phosphatase 2A, Receptor Type Tyrosine Protein Phosphatase S, Transient Receptor Potential Cation Channel Subfamily M Member 7, and Vascular Endothelial Growth Factor A
Key MoA Adenylate Cyclase Type 5 Inhibitor, Fibroblast Growth Factor 4 Activator, Gap Junction Alpha 1 Protein Inhibitor, N-Formyl Peptide Receptor 2 Agonist, N-Formyl Peptide Receptor 3 Agonist, Nitric Oxide Synthase Inducible Inhibitor, Protein Phosphatase 2A Inhibitor, Receptor Type Tyrosine Protein Phosphatase S Inhibitor, Transient Receptor Potential Cation Channel Subfamily M Member 7 Blocker, and Vascular Endothelial Growth Factor A Activator
Key RoA Oral, Intracardiac, Intracoronary, Intradermal, Intravenous, Parenteral, and Topical
Key molecule types Small Molecule, Recombinant Protein, Gene Therapy, Peptide, Synthetic Peptide, Cell Therapy, and Oligonucleotide
Key companies Anagenics Ltd, Angionetics Inc, AstraZeneca Plc, BioCardia Inc, Chrysalis BioTherapeutics Inc, CohBar Inc, Eight Plus One Pharmaceutical Co Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Ischemia (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Myocardial Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myocardial Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myocardial Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Ischemia (Cardiovascular)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myocardial Ischemia (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myocardial Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Anagenics Ltd
Angionetics Inc
AstraZeneca Plc
BioCardia Inc
Chrysalis BioTherapeutics Inc
CohBar Inc
Eight Plus One Pharmaceutical Co Ltd
Guangzhou Magpie Pharmaceutical Co Ltd
Imbria Pharmaceuticals Inc
Lixte Biotechnology Holdings Inc
NervGen Pharma Corp
NoNO Inc
Omniox Inc
Q BioMed Inc
Symvivo Inc
Vasade Biosciences Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Myocardial Ischemia – Overview

Myocardial Ischemia – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Myocardial Ischemia – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Myocardial Ischemia – Companies Involved in Therapeutics Development

Anagenics Ltd

Angionetics Inc

AstraZeneca Plc

BioCardia Inc

Chrysalis BioTherapeutics Inc

CohBar Inc

Eight Plus One Pharmaceutical Co Ltd

Guangzhou Magpie Pharmaceutical Co Ltd

Imbria Pharmaceuticals Inc

Lixte Biotechnology Holdings Inc

NervGen Pharma Corp

NoNO Inc

Omniox Inc

Q BioMed Inc

Symvivo Inc

Vasade Biosciences Inc

Myocardial Ischemia – Drug Profiles

alferminogene tadenovec – Drug Profile

Product Description

Mechanism Of Action

History of Events

AZD-8601 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BJY-802 – Drug Profile

Product Description

Mechanism Of Action

CardiAMP – Drug Profile

Product Description

Mechanism Of Action

History of Events

CMK-103 – Drug Profile

Product Description

Mechanism Of Action

DT-010 – Drug Profile

Product Description

Mechanism Of Action

Gene Therapy for Myocardial Ischemia – Drug Profile

Product Description

Mechanism Of Action

Humanin – Drug Profile

Product Description

Mechanism Of Action

History of Events

LB-100 – Drug Profile

Product Description

Mechanism Of Action

History of Events

MAN-04 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ninerafaxstat – Drug Profile

Product Description

Mechanism Of Action

NVG-291R – Drug Profile

Product Description

Mechanism Of Action

History of Events

OMX-4.80P – Drug Profile

Product Description

Mechanism Of Action

History of Events

PMC-6 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology – Drug Profile

Product Description

Mechanism Of Action

rusalatide acetate – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Antagonize TRPM7 for Oncology, Ophthalmology, Cardiovascular and Central nervous System Disorders – Drug Profile

Product Description

Mechanism Of Action

XG-19 – Drug Profile

Product Description

Mechanism Of Action

Myocardial Ischemia – Dormant Projects

Myocardial Ischemia – Discontinued Products

Myocardial Ischemia – Product Development Milestones

Featured News & Press Releases

Oct 21, 2021: BioCardia announces first patient treated in CardiAMP cell therapy trial for chronic myocardial ischemia

Jun 22, 2021: BioCardia to present CardiAMP cell therapy clinical trial data at European Society of Cardiology Heart Failure 2021

Feb 20, 2019: Phase 1 data published in Nature Communications show potential of mRNA encoding VEGF-A as a regenerative therapeutic

Jan 09, 2017: Angionetics Research Head Authors Scientific American Article on Therapeutic Angiogenesis as Potential New Treatment Approach for Ischemic Heart Disease

Sep 12, 2016: Angionetics’ Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease

May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities

Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum

Sep 03, 2014: Taxus Cardium to Present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City

Aug 13, 2014: Taxus Cardium Announces Biological and Clinical Advances in Angiogenic Gene Therapy for Heart Disease in Journal of Cardiovascular Pharmacology

Jun 12, 2014: Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International Convention

Jan 27, 2014: Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings

May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy

Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease

Oct 25, 2012: Cytori Announces Japanese Approval For Clinical Studies Of Cardiovascular And Chronic Liver Disease Cell Therapy

Mar 20, 2012: Cardium Therapeutics Initiates Generx Phase III Clinical Registration Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Myocardial Ischemia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Myocardial Ischemia – Pipeline by Anagenics Ltd, 2022

Myocardial Ischemia – Pipeline by Angionetics Inc, 2022

Myocardial Ischemia – Pipeline by AstraZeneca Plc, 2022

Myocardial Ischemia – Pipeline by BioCardia Inc, 2022

Myocardial Ischemia – Pipeline by Chrysalis BioTherapeutics Inc, 2022

Myocardial Ischemia – Pipeline by CohBar Inc, 2022

Myocardial Ischemia – Pipeline by Eight Plus One Pharmaceutical Co Ltd, 2022

Myocardial Ischemia – Pipeline by Guangzhou Magpie Pharmaceutical Co Ltd, 2022

Myocardial Ischemia – Pipeline by Imbria Pharmaceuticals Inc, 2022

Myocardial Ischemia – Pipeline by Lixte Biotechnology Holdings Inc, 2022

Myocardial Ischemia – Pipeline by NervGen Pharma Corp, 2022

Myocardial Ischemia – Pipeline by NoNO Inc, 2022

Myocardial Ischemia – Pipeline by Omniox Inc, 2022

Myocardial Ischemia – Pipeline by Q BioMed Inc, 2022

Myocardial Ischemia – Pipeline by Symvivo Inc, 2022

Myocardial Ischemia – Pipeline by Vasade Biosciences Inc, 2022

Myocardial Ischemia – Dormant Projects, 2022

Myocardial Ischemia – Dormant Projects, 2022 (Contd..1)

Myocardial Ischemia – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Myocardial Ischemia, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

  • What are the key targets in the myocardial ischemia pipeline market?

    The key targets in the myocardial ischemia pipeline market are Adenylate Cyclase Type 5, Fibroblast Growth Factor 4, Gap Junction Alpha 1 Protein, N-Formyl Peptide Receptor 2, N-Formyl Peptide Receptor 3, Nitric Oxide Synthase Inducible, Protein Phosphatase 2A, Receptor Type Tyrosine Protein Phosphatase S, Transient Receptor Potential Cation Channel Subfamily M Member 7, and Vascular Endothelial Growth Factor A.

  • What are the key MoA in the myocardial ischemia pipeline market?

    The key MoA in the myocardial ischemia pipeline market are Adenylate Cyclase Type 5 Inhibitor, Fibroblast Growth Factor 4 Activator, Gap Junction Alpha 1 Protein Inhibitor, N-Formyl Peptide Receptor 2 Agonist, N-Formyl Peptide Receptor 3 Agonist, Nitric Oxide Synthase Inducible Inhibitor, Protein Phosphatase 2A Inhibitor, Receptor Type Tyrosine Protein Phosphatase S Inhibitor, Transient Receptor Potential Cation Channel Subfamily M Member 7 Blocker, and Vascular Endothelial Growth Factor A Activator.

  • What are the key RoA in the myocardial ischemia pipeline market?

    The key RoA in the myocardial ischemia pipeline market are oral, intracardiac, intracoronary, intradermal, intravenous, parenteral, and topical.

  • What are the key molecule types in the myocardial ischemia pipeline market?

    The key molecule types in the myocardial ischemia pipeline market are small molecule, recombinant protein, gene therapy, peptide, synthetic peptide, cell therapy, and oligonucleotide.

  • What are the key companies in the myocardial ischemia pipeline market?

    The key companies in the myocardial ischemia pipeline market are Anagenics Ltd, Angionetics Inc, AstraZeneca Plc, BioCardia Inc, Chrysalis BioTherapeutics Inc, CohBar Inc, Eight Plus One Pharmaceutical Co Ltd.

Myocardial Ischemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Myocardial Ischemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Myocardial Ischemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.